About this trial
The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two rural). The study will include 160 adult participants with either solid tumors or hematologic malignancies who have been taking oral anticancer agents for at least six months.
This study will have two groups of participants, a pre- and post-implementation group. In the pre-implementation of the program group, investigators will administer a survey to the 80 participants and gather information about their medication prior to their enrollment of the program. Similarly, 80 participants who have been enrolled into this program for at least 6 months will serve as the post-implementation group. These patients will be administered the same survey. The results from both groups will be analyzed to see how effective the medication adherence program is.
Eligibility criteria
Qualifiers
Adult (age ≥21 years-old) patients
Diagnosed with a solid or hematologic malignancy
Monotherapy on oral anticancer agent on treatment for at least 6 months
Disqualifiers
Patients on time-limited or intermittent therapy (non-continuous)
Patients on comfort (end-of-life) care
Patients enrolled on hospice
Trial design
Treatments tested in this trial
- Multilevel Adherence Intervention
Treatment groups
Sponsors and collaborators
UNC Lineberger Comprehensive Cancer Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator